Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
EndocrinologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Emerging infectious diseases
- Publicado em
- 1 mar 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, Patrick P J Phillips, Nigel A Scott, Kia E Bryant, Rodney Dawson, Sandra Wagner Cardoso, Wadzanai Samaneka, Melissa Engle et al.
Descritores MeSH
- Diabetes Mellitus
- Antibiotics, Antitubercular
- Rifampin
- Tuberculosis
- Antitubercular Agents
- Diabetes Complications
- Treatment Outcome
- Humans
- Aged
- Female
Veja também
Estudos relacionados
- Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: a Bayesian network meta-analysis
- Safety, Efficacy, and Pharmacokinetics of Daily Optimized Doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis
- Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment-A Systematic Review and Meta-analysis
- A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs